Drug Type Small molecule drug |
Synonyms + [7] |
Mechanism FGFRs antagonists(Fibroblast growth factor receptors antagonists), FLT3 inhibitors(Tyrosine-protein kinase receptor FLT3 inhibitors), HPK1 inhibitors(Mitogen-activated protein kinase kinase kinase kinase 1 inhibitors) + [3] |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationSpecial Review Project (CN), Orphan Drug (US) |
Molecular FormulaC22H23FN6OS |
InChIKeyAVIOBQFPAGEICQ-UHFFFAOYSA-N |
CAS Registry2070931-57-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced gastric carcinoma | Phase 2 | CN | 25 Jun 2022 | |
Colorectal Cancer | Phase 2 | CN | 29 Nov 2021 | |
Refractory acute myeloid leukemia | Phase 2 | CN | 16 Sep 2021 | |
Relapsing acute myeloid leukemia | Phase 2 | CN | 16 Sep 2021 | |
Myelodysplastic Syndromes | Phase 2 | CN | 09 Sep 2021 | |
Advanced Gastric Adenocarcinoma | Phase 1 | CN | 01 Jun 2022 | |
Gastrooesophageal junction cancer | Phase 1 | CN | 01 Jun 2022 | |
Advanced Colorectal Adenocarcinoma | Phase 1 | CN | 31 Jan 2022 | |
Metastatic Colorectal Carcinoma | Phase 1 | CN | 31 Jan 2022 | |
Acute Myeloid Leukemia | Phase 1 | AU | 01 Aug 2018 |
Company_Website Manual | Phase 1 | Acute Myeloid Leukemia FLT3野生型 | - | (otibdqdcsa) = nltewvydqk ttbohvyath (vvhuzsueku ) View more | Positive | 01 Oct 2023 |